Opdivo-Yervoy (nivolumab-ipilimumab)

pCPA File Number: 21557

Negotiation Status:

Concluded with an LOI

Indication(s):

OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable malignant pleural mesothelioma (MPM) who have not received prior systemic therapy for MPM

Sponsor/Manufacturer:

Bristol Myers Squibb Canada Inc.

CADTH Project Number:

PC0229

pCPA Engagement Letter Issued:

2021-10-29

Negotiation Process Concluded:

2022-01-18